ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 523

Mortality Profile of Patients with Rheumatoid Arthritis in France and Its Change in 10 Years

Jerome Avouac1, Fazia Amrouche2, Christophe Meune3, Grégoire Rey4, Andre Kahan5 and Yannick Allanore6, 1Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, 2Paris Descartes University, Cochin Hospital, Paris, France, 3Cardiology department, Université Paris XIII, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Bobigny, France, 4Inserm-CépiDc, Hospital Bicêtre, Le Kremlin-Bicêtre, France, 5Service de Rhumatologie A, Hopital Cochin, Paris Cedex 14, France, 6Rheumatology, Paris Descartes University, Paris, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cardiovascular disease, Infection, morbidity and mortality, respiratory disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is associated with an excess of mortality. This risk depends on the disease activity, severity and associated comorbidities. Our objective was to study the mortality profile of RA patients in France using multiple-cause-of-death analysis.

Methods: Data were collected between 2000 and 2011 in the French Epidemiological Center for the Medical Causes of Death database, and death certificates issued upon the death of an adult for whom RA was an underlying cause of death (UCD) or an associated cause of death (ACD) were evaluated using multiple-cause-of-death analysis. Sex, age, sex ratio, standardized mortality rates, as well as frequency of the various causes of death were assessed. For the main causes of death, the observed number of deaths in relation to the expected number of deaths (O/E ratio) was calculated to measure the strength of association between RA listed as an ACD and the corresponding UCD.

Results: During the study period, 13,208 deaths related to RA were identified. RA was identified as the UCD in 4597 (35%) certificates. The number of certificates mentioning RA as the UCD decreased from 41% to 27% between 2000 and 2011. The mean±SD at death was 79 ± 9 years (51% with ≥80 years). The female: male ratio was 3.2 and remained stable during the follow-up period. This ratio was significantly higher in the population where RA was the UCD (4.1 vs. 2.8 p <0.001). The mean standardized mortality rate was 0.25 per 105 million people (range 0.21-0.28), and remained stable throughout the period. When RA was the UCD (n=4,597), the main ACDs were cardiovascular diseases (29%), infectious diseases (22%), and respiratory diseases (17%). When RA was an ACD (n=8,611), the most common UCDs were cardiovascular diseases (35% of certificates, including 877/3032 ischemic heart disease), neoplasms (14%), respiratory disease (9%) and infectious diseases (7%). The overall O/E ratio was >1 for infectious (3.58), respiratory (1.38) and cardiovascular diseases (1.25), but was <1 for neoplasms.

Conclusion: This is the first national study using a multiple-cause-of-death analysis to study the mortality profile in RA. Our results show that mortality related to cardiovascular, respiratory and infectious diseases is highly associated with RA. These data support the need to expand new strategies to prevent infectious and cardiovascular diseases in order to improve survival of RA patients.


Disclosure: J. Avouac, None; F. Amrouche, None; C. Meune, None; G. Rey, None; A. Kahan, None; Y. Allanore, None.

To cite this abstract in AMA style:

Avouac J, Amrouche F, Meune C, Rey G, Kahan A, Allanore Y. Mortality Profile of Patients with Rheumatoid Arthritis in France and Its Change in 10 Years [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/mortality-profile-of-patients-with-rheumatoid-arthritis-in-france-and-its-change-in-10-years/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-profile-of-patients-with-rheumatoid-arthritis-in-france-and-its-change-in-10-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology